In an effort to help curb the ongoing epidemic of prescription opioid abuse and overdoses, the US Food and Drug Administration (FDA) is tightening the indications for long-acting and extended-release versions of these drugs and is requiring the drugs� manufacturers to conduct long-term postmarketing studies.
�The FDA is concerned about inappropriate use of [opioid pain medications], which has reached epidemic proportions in the United States,� said FDA Commissioner Margaret A. Hamburg, MD, during a press briefing in September.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados